HLA-DQ AntigensHIV SeronegativityPrognosisHLA-B27 AntigenHLA-DR AntigensHLA-DR4 AntigenHelicobacter pyloriHelicobacter InfectionsAutoantibodiesRetrospective StudiesDyspepsiaBreast NeoplasmsTreatment OutcomeTumor Markers, BiologicalProspective StudiesSurvival AnalysisReceptor, erbB-2ImmunohistochemistryHLA-DRB1 ChainsSensitivity and SpecificityFollow-Up StudiesSurvival RateHepatitis B e AntigensPolymerase Chain ReactionPredictive Value of TestsHepatitis C AntibodiesHLA-B AntigensHepatitis BCase-Control StudiesDisease-Free SurvivalNeoplasm StagingHepatitis B virusLymphatic MetastasisGastritisHistocompatibility TestingRheumatoid FactorAntibodies, AntinuclearGenotypeReceptors, EstrogenMultivariate AnalysisHepatitis CBiological MarkersDNA, ViralGastric MucosaSpondylitis, AnkylosingPrevalenceEnzyme-Linked Immunosorbent AssayArthritis, RheumatoidHepatitis B, ChronicHepatitis B Surface AntigensHIV InfectionsHepacivirusReceptors, ProgesteroneTime FactorsTuberculosis, PulmonaryCohort StudiesAlanine TransaminaseAntineoplastic Combined Chemotherapy ProtocolsImmunoglobulin GDisease ProgressionAllelesHIV SeropositivityHLA-DP AntigensHLA-DR3 AntigenInterferon-alphaBiopsyImmunoenzyme TechniquesKaplan-Meier EstimateRisk FactorsAIDS-Related Opportunistic InfectionsAge of OnsetDrug Therapy, CombinationPrednisoneProportional Hazards ModelsAntiviral AgentsHLA-D AntigensGliadinChemotherapy, AdjuvantGenetic Predisposition to DiseaseSeverity of Illness IndexHLA-DQ beta-ChainsRecurrenceHLA-DQ alpha-ChainsGene Expression Regulation, NeoplasticCeliac DiseaseAntibodiesLung NeoplasmsChronic DiseaseNeoplasm Recurrence, LocalChi-Square DistributionHepatitis C, ChronicImmunoglobulin MEpitopesMutationAntibodies, MonoclonalPhenotypeCarcinoma, Squamous CellRenal DialysisTuberculosisNeoplasm Proteins